Download Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Dipeptidyl Peptidase IV Inhibitors Market: By Drug Type, By Distribution channel and Region Forecast 2021-2032
Dipeptidyl Peptidase IV Inhibitors Market: By Drug Type, By Distribution channel and Region Forecast 2021-2032
Report ID:15837
Published Date:Oct 2025
No of Pages:205
Format:
Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market size was valued at US$ 18.1 billion in 2025 and is expected to reach US$ 25.5 billion by 2032, growing at a significant CAGR of 5.0% from 2026-2032. market is expected to fuel the dipeptidyl peptidase IV inhibitors market. Geographically, dipeptidyl peptidase IV Inhibitors market is in booming stage in nature with several local and international players operating in the market. Launching of new products, approvals from various regulatory authorities such as U.S. Food and Drug Administration (U.S. FDA), acquisitions & mergers, and collaborations are some key strategies followed by various pharmaceutical companies for increasing their share in dipeptidyl peptidase IV inhibitors market.
Study Period
2026-2032Base Year
2025CAGR
5%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
The excellent safety profile of dipeptidyl peptidase IV inhibitors, growing investments in the R&D activities, convenience benefit of being an oral medication, and acceptance of dipeptidyl peptidase IV inhibitors in oral antidiabetic drug class might fuel the dipeptidyl peptidase IV inhibitors market over the forecast period. Furthermore, favourable reimbursement policies for diabetes treatment, and low cost for dipeptidyl peptidase IV inhibitors expected to boost the dipeptidyl peptidase-IV inhibitors market over the forecast period. However, stringent regulatory policies, adverse effects associated with dipeptidyl peptidase IV inhibitors might hamper the dipeptidyl peptidase IV inhibitors market growth over the forecast period.
|
Report Benchmarks |
Details |
|
Report Study Period |
2026-2032 |
|
Market CAGR |
5% |
|
By Drug Type |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market size was valued at US$ 18.1 billion in 2025 and is expected to reach US$ 25.5 billion by 2032, growing at a significant CAGR of 5.0% from 2026-2032.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
AstraZeneca Plc., Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck & Co, Inc., Mitsubishi Tanabe Pharma Corporation, Novartis AG, Takeda Pharmaceutical Company Limited are indeed major pharmaceutical companies that have been involved in the development and marketing of Dipeptidyl Peptidase-4 (DPP-4) inhibitors
Content Updated Date: Jan 2026
| 1.Executive Summary |
| 2.Global Dipeptidyl Peptidase Iv Dpp Iv Inhibitors Market Introduction |
| 2.1.Global Dipeptidyl Peptidase Iv Dpp Iv Inhibitors Market - Taxonomy |
| 2.2.Global Dipeptidyl Peptidase Iv Dpp Iv Inhibitors Market - Definitions |
| 2.2.1.Drug Type |
| 2.2.2.Distribution Channel |
| 2.2.3.Geography |
| 2.2.4.Region |
| 3.Global Dipeptidyl Peptidase Iv Dpp Iv Inhibitors Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Dipeptidyl Peptidase Iv Dpp Iv Inhibitors Market Analysis, 2021-2025 and Forecast 2026-2032 |
| 4.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Dipeptidyl Peptidase Iv Dpp Iv Inhibitors Market By Drug Type, 2021-2025 and Forecast 2026-2032 (Sales Value USD Million) |
| 5.1. Sitagliptin |
| 5.1.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Vildagliptin |
| 5.2.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Saxagliptin |
| 5.3.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Linagliptin |
| 5.4.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others |
| 5.5.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global Dipeptidyl Peptidase Iv Dpp Iv Inhibitors Market By Distribution Channel, 2021-2025 and Forecast 2026-2032 (Sales Value USD Million) |
| 6.1. Hospital Pharmacies |
| 6.1.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Retail Pharmacies |
| 6.2.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Online Pharmacies |
| 6.3.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Dipeptidyl Peptidase Iv Dpp Iv Inhibitors Market By Geography, 2021-2025 and Forecast 2026-2032 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Asia Pacific |
| 7.2.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Europe |
| 7.3.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Middle East |
| 7.5.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.Global Dipeptidyl Peptidase Iv Dpp Iv Inhibitors Market By Region, 2021-2025 and Forecast 2026-2032 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Dipeptidyl Peptidase Iv Dpp Iv Inhibitors Market ,2021-2025 and Forecast 2026-2032 (Sales Value USD Million) |
| 9.1. Drug Type Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Sitagliptin |
| 9.1.2.Vildagliptin |
| 9.1.3.Saxagliptin |
| 9.1.4.Linagliptin |
| 9.1.5.Others |
| 9.2. Distribution Channel Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Hospital Pharmacies |
| 9.2.2.Retail Pharmacies |
| 9.2.3.Online Pharmacies |
| 9.3. Geography Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.North America |
| 9.3.2.Asia Pacific |
| 9.3.3.Europe |
| 9.3.4.Latin America |
| 9.3.5.Middle East |
| 9.4. Country Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Dipeptidyl Peptidase Iv Dpp Iv Inhibitors Market ,2021-2025 and Forecast 2026-2032 (Sales Value USD Million) |
| 10.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Sitagliptin |
| 10.1.2.Vildagliptin |
| 10.1.3.Saxagliptin |
| 10.1.4.Linagliptin |
| 10.1.5.Others |
| 10.2. Distribution Channel Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Hospital Pharmacies |
| 10.2.2.Retail Pharmacies |
| 10.2.3.Online Pharmacies |
| 10.3. Geography Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.North America |
| 10.3.2.Asia Pacific |
| 10.3.3.Europe |
| 10.3.4.Latin America |
| 10.3.5.Middle East |
| 10.4. Country Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Dipeptidyl Peptidase Iv Dpp Iv Inhibitors Market ,2021-2025 and Forecast 2026-2032 (Sales Value USD Million) |
| 11.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Sitagliptin |
| 11.1.2.Vildagliptin |
| 11.1.3.Saxagliptin |
| 11.1.4.Linagliptin |
| 11.1.5.Others |
| 11.2. Distribution Channel Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Hospital Pharmacies |
| 11.2.2.Retail Pharmacies |
| 11.2.3.Online Pharmacies |
| 11.3. Geography Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.North America |
| 11.3.2.Asia Pacific |
| 11.3.3.Europe |
| 11.3.4.Latin America |
| 11.3.5.Middle East |
| 11.4. Country Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Dipeptidyl Peptidase Iv Dpp Iv Inhibitors Market ,2021-2025 and Forecast 2026-2032 (Sales Value USD Million) |
| 12.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Sitagliptin |
| 12.1.2.Vildagliptin |
| 12.1.3.Saxagliptin |
| 12.1.4.Linagliptin |
| 12.1.5.Others |
| 12.2. Distribution Channel Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Hospital Pharmacies |
| 12.2.2.Retail Pharmacies |
| 12.2.3.Online Pharmacies |
| 12.3. Geography Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.North America |
| 12.3.2.Asia Pacific |
| 12.3.3.Europe |
| 12.3.4.Latin America |
| 12.3.5.Middle East |
| 12.4. Country Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Dipeptidyl Peptidase Iv Dpp Iv Inhibitors Market ,2021-2025 and Forecast 2026-2032 (Sales Value USD Million) |
| 13.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Sitagliptin |
| 13.1.2.Vildagliptin |
| 13.1.3.Saxagliptin |
| 13.1.4.Linagliptin |
| 13.1.5.Others |
| 13.2. Distribution Channel Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Hospital Pharmacies |
| 13.2.2.Retail Pharmacies |
| 13.2.3.Online Pharmacies |
| 13.3. Geography Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.North America |
| 13.3.2.Asia Pacific |
| 13.3.3.Europe |
| 13.3.4.Latin America |
| 13.3.5.Middle East |
| 13.4. Country Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.AstraZeneca Plc. |
| 14.2.2.Boehringer Ingelheim GmbH |
| 14.2.3.Eli Lilly and Company |
| 14.2.4.Merck & Co, Inc. |
| 14.2.5.Mitsubishi Tanabe Pharma Corporation |
| 14.2.6.Novartis AG |
| 14.2.7.Takeda Pharmaceutical Company Limited |
| 14.2.8.Sanofi |
| 14.2.9.Bristol-Myers Squibb |
| 14.2.10.GlaxoSmithKline Plc. |
| 14.2.11.Pfizer, Inc. |
| 14.2.12.Otsuka Holdings Co. Ltd. |
| 14.2.13.Ornamed Pharmaceutical, Inc. |
| 14.2.14.Dr. Reddys Laboratories, Ltd. |
| 14.2.15.Novo Nordisk A/S |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.